“Since our company’s inception a little over a year ago, AllinkBio has rapidly advanced from lead asset PCC to clinical development stage,” said Hui Feng, Ph.D., Founder and Chief Executive Officer of AllinkBio. “We are grateful for the continued support from existing shareholders and delighted to welcome new investors who recognize both our scientific excellence and capability of translating scientific findings into clinical applications. Their support enables us to accelerate the development of our diverse pipeline spanning multiple modalities including next-generation ADCs and bispecific antibodies targeting oncology and immunology diseases. Looking ahead, we are poised to achieve multiple pipeline milestones in the coming months as we pursue our long-term mission of bringing innovative therapeutics to patients with significant unmet medical needs.”